Design of preclinical combination studies

Alexander Donev and Bader Almohaimeed

University of Manchester, UK

Talk Outline



Preliminaries

- What is a drug combination?
- Data structures. Ray design

2 Methods for evaluating drug interactions

- Combination index
- Sources of variability

3 Statistical models

- Two drugs
- Analysis of data
- 4

Design challenges

- Types of studies and models
- Design optimality
- R package (in early stage of preparation)
- Example 1. D-optimum designs for NL and GNL models
- Example 2. D-optimum designs for NLME and GNLME models

Discussion

Preliminaries

Methods for evaluating drug interactions Statistical models Design challenges Discussion

What is a drug combination? Data structures. Ray design

What is a drug combination?

Definition of bioassay

Scientific experiment for determining the effect of a compound or other substance.

Drug combination

Medications which contain two, or more, different compounds.

Preliminaries

Methods for evaluating drug interactions Statistical models Design challenges Discussion

What is a drug combination? Data structures. Ray design

Combinations of drugs

Combinations of drugs may be useful when:

- using one drug is not sufficient to control a disease;
- the required dose is too high and has undesirable side effects;

Pre-clinical experiments



Figure: Typical 96-wells plate

What is a drug combination? Data structures. Ray design

Data structures

- Doses of drugs: d_{ij1} and d_{ij2} , in constant ratios $R_i = d_{ij1}/d_{ij2}$, i, i = 3, ..., r, j, j = 1, ..., c;
- Response of interest Y_{ij} measured at the doses $x_{ij} = d_{ij1} + d_{ij2}$.

Preliminaries

Methods for evaluating drug interactions Statistical models Design challenges Discussion

What is a drug combination? Data structures. Ray design

Ray design





The name come from!

Radiating style

Combination index Sources of variability

Methods for evaluating drug interactions

Combination index

The drug interactions at combination of two drugs can be characterized as

$$\frac{d_1}{D_{y_0,1}} + \dots + \frac{d_2}{D_{y_0,2}} \begin{cases} <1, & \mathsf{Synergy};\\ =1, & \mathsf{Additivity};\\ >1, & \mathsf{Antagonism}, \end{cases}$$

- d_i are doses of each drug in the combination of the k drugs resulting in effect y_0 ;
- $D_{y_0,i}$ are the doses of drugs that result in the effect y_0 for each respective drug given alone.

Combination index Sources of variability

Sources of variability

- occasions
- batches of cultures
- plates
- . . .

Discussion

Two drugs Analysis of data

Statistical models

Distribution of response

$$Y \Longrightarrow$$
 Exponential family (EFD)

Nonlinear predictor for each ray

$$\eta(\mathbf{x}_{ij}, oldsymbol{ heta}) = \gamma + rac{\delta - \gamma}{\left(1 + 10^{\left(\mathbf{x}_{ij} - lpha_i
ight)eta_i}
ight)^{\lambda_i}}$$

where $\boldsymbol{\theta} = (\alpha_i \ \beta_i \ \gamma \ \delta \ \lambda_i), \ i = 1, \dots, r.$

Link function ...

between
$$\eta(x_{ij}, \theta)$$
 and $E[Y] = \mu_{ij} \Longrightarrow g(\mu_{ij}) = \eta(x_{ij})$.

Preliminaries Methods for evaluating drug interactions Statistical models

Design challenges Discussion Two drugs Analysis of data

Hill model (1913)

4 parameters

$$Y_{ij} = \gamma + rac{\delta - \gamma}{1 + 10^{(x_{ij} - lpha_i)eta_i}} + arepsilon_{ij}.$$

where:

- γ Minimum response
- δ Maximum response
- α LogIC50, or logEC50)
- β Hill slope
- ϵ Experimental error, $\varepsilon \sim \textit{N}(0, \sigma^2)$

Example of cancer data



Preliminaries Methods for evaluating drug interactions Statistical models

Design challenges Discussion Two drugs Analysis of data

Alternative models

Special cases

• Minimum response = 0

$$Y_{ij} = rac{\delta}{1+10^{\left(x_{ij}-lpha_i
ight)eta_i}}+\epsilon_{ij}.$$

• Minimum response = 0 and Maximum response = 1

$$Y_{ij} = rac{1}{1+10^{\left(x_{ij}-lpha_i
ight)eta_i}}+\epsilon_{ij}.$$

Asymmetric

$$Y_{ij} = \gamma + rac{\delta - \gamma}{\left(1 + 10^{\left(x_{ij} - lpha_i,
ight)eta_i}
ight)^{\lambda_i}} + \epsilon_{ij},$$

Discussion

Two drugs Analysis of data

Nonlinear mixed effects models

Example - all parameters random

۲

 $Y_{ij} = (\gamma + \varepsilon_{\gamma}) + \frac{(\delta + \varepsilon_{\delta}) - (\gamma + \varepsilon_{\gamma})}{\left(1 + 10^{(x_{ij} - (\alpha + \varepsilon_{\alpha}))(\beta + \varepsilon_{\beta})}\right)^{(\lambda + \varepsilon_{\lambda})}} + \epsilon_{ij},$

• where $\theta_{p_i=\alpha_i,\beta_i,\gamma_i,\delta_i,\lambda_i} \sim EFD(\theta_p,\phi_p)$, and $\epsilon_{ij} \sim EFD(0,\phi)$.

 Related work include: Mentré, Mallet, Baccar (1997), Fedorov, Gagnon, Leonov (2002), Han and Chaloner (2004), Gagnon and Leonov (2005) and Atkinson, A.C. (2008).

Two drugs Analysis of data

Analysis of data

- There are many examples of successful combination studies in the literature, e.g.:
 - ▷ Loewe, S. 1957;
 - ▷ Chou and Talalay, 1984;
 - ▷ Berenbaum MC, 1985;
 - ▷ Faessel,H.M. et. al. 1998;
 - Straetemans R. et al. 2005.

Discussion

- Extensive discussions of the scientific background of such studies, include:
 - ▷ Berenbaum MC, 1989;
 - Chou, T. C 1991;
 - Greco et. al. 1995;
 - ▷ Tallarida, R. J. 2000.
 - ▷ Chou, T.C et. al. 2006.

Two drugs Analysis of data

Analysis of data

- Recently, there has been substantial interest in the appropriate statistical methods for analysis of data obtained in combination studies including:
 - ▷ Brun YF et al. 2010;
 - ▷ Chou, T. C 2010;
 - ▷ Donev, A. N. 2010;
 - ▷ Fujimoto Junya et. al. 2010;
 - ▷ Kong M et al. 2010;
 - ▶ Lee JJ et al. 2010;
 - ▷ Palomares et al. 2010;
 - ▷ Peterson JJ 2010;
 - ▷ Straetemans R. et al. 2010;
 - ▶ Yan Han et al. 2010;

Two drugs Analysis of data

Analysis of data

- Some of these statistical methods of combination studies have been implemented as statistical packages in the free statistical software R include:
 - \triangleright drc \Longrightarrow Analysis of dose-response curves

Discussion

- \triangleright grofit \Longrightarrow Fitting biological growth curves with R
- ▷ dosefinding ⇒> Planning and Analyzing Dose Finding experiments
- ▷ mixlow ⇒ An R Package for Assessing Drug Synergism/Antagonism
- These packages are regularly improved and updated!

Types of studies and models

Design optimality R package (in early stage of preparation) Example 1. D-optimum designs for NL and GNL models Example 2. D-optimum designs for NLME and GNLME models

Design challenges

- Less attention has been given to the choice of suitable experimental designs for such studies;
- Need to develop the necessary methodology;
- Need to develop an R package;

Preliminaries Types of studies and models
Methods for evaluating drug interactions Design optimality
Statistical models R package (in early stage of preparation)
Design challenges
Discussion Example 1. D-optimum designs for NL and GNLME models
Example 2. D-optimum designs for NLME and GNLME models

Design challenges

Types of studies

- Single compounds;
- Screeing compounds library for combinations using one design - population studies;
- Confirmatory experiments, safety studies, etc;
- Variety of error distributions (normal, binary, Poisson, etc).

Types of models

- Nonlinear (NL);
- Generalized nonlinear (GNL);
- Nonlinear mixed effects (NLME);
- Generalized nonlinear mixed effects (GNLME).

 Preliminaries
 Types of studies and models

 Methods for evaluating drug interactions
 Design optimality

 Statistical models
 R package (in early stage of preparation)

 Design challenges
 Example 1. D-optimum designs for NL and GNLME models

Optimality criteria

• The information matrix

$\mathbf{M} = \mathbf{X}^\mathsf{T} \mathbf{W} \mathbf{X}$

depends on:

the unknown parameters;

the covariance matrix of the observations \mathbf{W} .

• A common approach is to linearize:

Locally D-optimum design ξ^* :

 $\min |\mathbf{M}^{-1}(\xi, \boldsymbol{ heta})||_{\boldsymbol{ heta}=oldsymbol{ heta}_0}$

Pseudo-Bayesian D-optimum design ξ^* :

 $\min |\mathbf{M}^{-1}(\xi, \boldsymbol{\theta})||_{\boldsymbol{\theta} \in \boldsymbol{\theta}_0}$

Preliminaries Methods for evaluating drug interactions Statistical models Design optimality R package (in early stage of preparation) Example 1. D-optimum designs for NL and GNLME models Example 2. D-optimum designs for NLME and GNLME models

R package

State

- Early stage of preparation;
- Still developing code;

Search for D-optimum designs for models:

- Nonlinear (NL);
- Generalized nonlinear (GNL);
- Nonlinear mixed effects (NLME);
- Generalized nonlinear mixed effects (GNLME).

Preliminaries Methods for evaluating drug interactions Statistical models Design challenges Discussion Discussion Discussion Design challenges Discussion Design challenges Discussion Design challenges Design ch

Example 1. D-optimum designs for NL and GNL models

Table: Parameters values

Design	α	β	γ	δ	λ	σ^2	κ	v	т
Local	1.92	0.94	0.1	1.1	1.5	1	0.5	1.5	$2 \times p$
Pseudo-Bayesian	[1.31,3.01]	[0.50, 1.15]	0.1	1.1	1.5	1	0.5	1.5	$2 \times p$

where

 $\implies \alpha$, β , γ , δ and λ are models parameters;

 $\implies \kappa$ and v are parameters of gamma and inverse Gaussian distribution;

 \implies *m* is the number of trials in binomial distribution.

Preliminaries Types of studies and models
Methods for evaluating drug interactions Design optimality
Statistical models
Design challenges Example 1. D-optimum designs for NL and GNL models
Discussion Example 2. D-optimum designs for NLME and GNLME models

Example 1: Locally D-optimum designs

Table: Locally D-optimum designs for Ray 4

Model	Design			Error		
parameter	point	Normal	Poisson	Binomial	Gamma	I-Gaussian
2-P	1	0.45	0.24	0.67	1.17	0.94
	2	5.55	2.71	7.19	10 (<i>max</i>)	10 (<i>max</i>)
3-P	1	0	0	0	0	0
	2	0.45	0.22	0.71	1.17	0.94
	3	5.56	2.52	7.51	10 (<i>max</i>)	10 (<i>max</i>)
4-P	1	0	0	0	0	0
	2	0.24	0.15	0.25	0.41	0.36
	3	2.07	1.41	2.17	3.39	3.03
	4	10 (<i>max</i>)				
5-P	1	0	0	0	0	0
	2	0.24	0.14	0.10	0.16	0.13
	3	2.05	1.48	0.71	1.28	1.17
	4	6.39	5.96	2.21	5.04	4.93
	5	10 (<i>max</i>)	10 (<i>max</i>)	5.10	10 (<i>max</i>)	10 (<i>max</i>)

Preliminaries Types of studies and models
Methods for evaluating drug interactions Design optimality
Statistical models
Design challenges
Example 1. D-optimum designs for NL and GNL models
Discussion
Example 2. D-optimum designs for NLME and GNLME models

Example 2: Pseudo-Bayesian D-optimum designs

Table: Pseudo-Bayesian D-optimal designs for Ray 4

Model	Design			Error		
parameter	point	Normal	Poisson	Binomial	Gamma	I-Gaussian
2-P	1	0.72	0.41	1.02	1.58	1.31
	2	6.49	3.47	8.13	10 (<i>max</i>)	10 (<i>max</i>)
3-P	1	0	0	0	0	0
	2	0.72	0.40	1.08	1.58	1.31
	3	6.49	3.27	8.45	10 (<i>max</i>)	10 (<i>max</i>)
4-P	1	0	0	0	0	0
	2	0.40	0.27	0.42	0.65	0.57
	3	2.56	1.85	2.66	3.88	3.52
	4	10 (<i>max</i>)				
5-P	1	0	0	0	0	0
	2	0.43	0.15	0.18	0.28	0.25
	3	2.63	0.87	1.02	1.61	1.42
	4	6.86	3.56	3.79	5.15	4.81
	5	10 (<i>max</i>)	10 (<i>max</i>)	10 (max)	10 (<i>max</i>)	10 (<i>max</i>)

Types of studies and models Design optimality R package (in early stage of preparation) Example 1. D-optimum designs for NL and GNL models Example 2. D-optimum designs for NLME and GNLME models

Verifying D-optimal designs for NLMs using GET



Alexander Donev and Bader Almohaimeed

Design of preclinical combination studies

Preliminaries Types of studies and models Methods for evaluating drug interactions Design optimality Statistical models Design optimality R package (in early stage of preparation) Example 1. D-optimum designs for NL and GNL models Discussion Example 2. D-optimum designs for NLME and GNLME mod

Optimum designs for GNLM with Poisson errors





Preliminaries Types of studies and models
Methods for evaluating drug interactions Statistical models
Design optimality
R package (in early stage of preparation)
Example 1. D-optimum designs for NL and GNL models
Discussion
Example 2. D-optimum designs for NLME and GNLME models

Optimum designs for GNLM models



Preliminaries Types of studies and models Methods for evaluating drug interactions Statistical models Design optimality Design challenges Discussion Discussion Statistical models Design optimum designs for NL and GNL models Example 2. D-optimum designs for NLME and GNLME models

Example 2. D-optimum designs for NLME and GNLME models

Model assumption:

• the model can be given as

$$Y_{ij} = (\gamma + \varepsilon_{\gamma}) + \frac{(\delta + \varepsilon_{\delta}) - (\gamma + \varepsilon_{\gamma})}{\left(1 + 10^{\left(x_{ij} - (\alpha + \varepsilon_{\alpha})\right)(\beta + \varepsilon_{\beta})}\right)^{(\lambda + \varepsilon_{\lambda})}} + \epsilon_{ij}, \tag{1}$$

• where $\theta_{p_i=\alpha_i,\beta_i,\gamma_i,\delta_i,\lambda_i} \sim EFD(\theta_p,\phi_p)$, and $\epsilon_{ij} \sim EFD(0,\phi)$.

Preliminaries Types of studies and models
Methods for evaluating drug interactions Design optimality
Statistical models R package (in early stage of preparation)
Design challenges Example 1. D-optimum designs for NL and GNL models
Discussion Example 2. D-optimum designs for NLME and GNLME models

Optimum designs for GNLME models

5 cases: Case 1: $\theta_{p_i} \sim N(\theta_p, \sigma_p^2) = ((1.69, 0.84, 2.90, 0.20, 1.5), (0.26, 0.03, 0.76, 0.01, 0.02))$ $\epsilon_{ii} \sim N(0, \sigma^2) = (0, 0.25)$ 2 Case 2: $\theta_{p_i} \sim \ln N(\theta_p, \sigma_p^2) = ((1.69, 0.84, 2.90, 0.20, 1.5), (0.26, 0.03, 0.76, 0.01, 0.02))$ $\epsilon_{ii} \sim \ln N(0, \sigma^2) = (0, 0.25)$ Case 3: $\boldsymbol{\theta}_{p_i} \sim \Gamma(\kappa_{\boldsymbol{\theta}_p}, \vartheta_{\boldsymbol{\theta}_p}) = ((1, 0.9, 1, 1, 1), (0.2, 0.3, 1, 0.02, 0.5))$ $\epsilon_{ii} \sim \Gamma(\kappa_{\epsilon}, \vartheta_{\epsilon}) = (1, 0.5)$ Case 4: $\boldsymbol{\theta}_{p_i} \sim \mathsf{I-G}(\mu_{\boldsymbol{\theta}_p}, \kappa_{\boldsymbol{\theta}_p}) = ((1, 0.9, 1, 0.1, 0.5), (0.1, 0.3, 1, 0.01, 0.02))$ $\epsilon_{ij} \sim I-G(\mu_{\epsilon}, \kappa_{\epsilon}) = (0.1, 0.3)$ 6 Case 5: $\theta_{p_i} \sim \ln N(\theta_p, \sigma_p^2)$ $\theta_{\alpha} \sim Exp(\lambda_{\alpha}) = (3.2)$

Preliminaries Types of studies and models
Design optimality
Statistical models
Design challenges
Discussion
Example 2. D-optimum designs for NLME and GNLME models

Example 3: Locally D-optimum designs for NLMEM

Table: Locally D-optimal designs for ray 4

Model	Design	Case						
parameter	point	1	2	3	4	5		
4-P	1	0	0	0	0	0		
	2	0.98	1.01	0.99	1.00	1.01		
	3	5.36	5.45	5.40	5.43	5.44		
	4	10 (<i>max</i>)						
5-P	1	0	0	0	0	0		
	2	0.24	0.29	0.24	0.33	0.29		
	3	1.67	1.92	1.68	2.31	1.92		
	4	5.47	5.92	5.28	6.67	5.95		
	5	10 (<i>max</i>)						



Challenges ahead!

Note: This work is part of Bader's PhD thesis and is currently been written up for submission to a journal.



 96-well picture was taken from: http://www.sz-wholesaler.com/p/893/905-1/96-well-cell-culture-plate-406392.html